Cardiovascular Interventional Center, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
J Zhejiang Univ Sci B. 2011 Aug;12(8):633-7. doi: 10.1631/jzus.B1101009.
As life expectancy increases, valvular heart disease is becoming more common. Management of heart disease and primarily valvular heart disease is expected to represent a significant proportion of healthcare provided to the elderly population. Recent years have brought a progression of surgical treatments toward less invasive strategies. This has given rise to percutaneous approaches for the correction of valvular heart disease. Percutaneous mitral valve repair using the MitraClip system (Abbott Vascular, Santa Clara, CA, USA) creates a double orifice and has been successfully used in selected patients with mitral regurgitation. We review the rationale, procedural aspects, and clinical data thus far available for the MitraClip approach to mitral regurgitation.
随着预期寿命的延长,心脏瓣膜疾病越来越常见。预计心脏病的治疗,尤其是心脏瓣膜疾病的治疗,将占为老年人群提供的医疗保健的很大一部分。近年来,外科治疗朝着微创策略发展。这为心脏瓣膜疾病的经皮治疗方法提供了可能。使用 MitraClip 系统(美国雅培血管公司,圣克拉拉,加利福尼亚州)进行经皮二尖瓣修复术可创建双孔,并已成功用于特定的二尖瓣反流患者。我们回顾了二尖瓣反流 MitraClip 治疗方法的基本原理、程序方面和迄今为止可用的临床数据。